Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial

(2020) Rakesh Popat et al.   HAEMATOLOGICA

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

(2020) Maria Gavriatopoulou et al.   LEUKEMIA

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma

(2020) Hanley N. Abramson   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Selinexor for advanced hematologic malignancies

(2020) Janek S. Walker et al.   LEUKEMIA & LYMPHOMA

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

(2020) Panagiotis Malandrakis et al.   OncoTargets and Therapy

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

(2020) Shih-Feng Cho et al.   Cancers

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Selinexor: First Global Approval

(2019) Yahiya Y. Syed   DRUGS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Kirollos S. Hanna   DRUGS

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

(2018) Hartmut Goldschmidt et al.   ANNALS OF HEMATOLOGY

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

(2016) Rudolph M. Navari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Guidance on the management of diarrhoea during cancer chemotherapy

(2014) Jervoise Andreyev et al.   LANCET ONCOLOGY

Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?

(2013) Ju-Xian Sun et al.   Asia-Pacific Journal of Clinical Oncology

A systematic review of dysgeusia induced by cancer therapies

(2010) Allan J. Hovan et al.   SUPPORTIVE CARE IN CANCER